Quarterly Financial Data (Unaudited)

12 Months Ended

Dec. 31, 2020

Quarterly Financial Information Disclosure [Abstract]

QUARTERLY FINANCIAL DATA (UNAUDITED)

The following table sets forth certain unaudited quarterly financial data for the eight quarters ended December 31, 2020. The unaudited information set forth below has been prepared on the same basis as the audited information contained herein and includes all adjustments necessary to present fairly the information set forth. The operating results for any quarter are not indicative of results for any future period. All amounts are in thousands except per share amounts.


	2020								2019
	Q1		Q2		Q3		Q4		Q1		Q2		Q3		Q4
Revenues	$	13,076	$	21,553	$	57,763	$	25,800	$	8,071	$	17,548	$	21,958	$	54,851
Operating expenses	$	57,598	$	59,450	$	61,464	$	69,232	$	51,968	$	51,052	$	51,206	$	53,382
Net (loss) income	$	(42,974)	$	(35,965)	$	(1,508)	$	(40,675)	$	(42,203)	$	(30,356)	$	(27,361)	$	4,501
Net (loss) income attributable to non-controlling interest	$	(61)	$	(36)	$	42	$	(71)	$	(53)	$	(72)	$	(54)	$	(54)
Net (loss) income attributable to Sangamo Therapeutics, Inc.	$	(42,913)	$	(35,929)	$	(1,550)	$	(40,604)	$	(42,150)	$	(30,284)	$	(27,307)	$	4,555
Basic and diluted net (loss) income per share attributable to Sangamo Therapeutics, Inc.	$	(0.37)	$	(0.26)	$	(0.01)	$	(0.29)	$	(0.41)	$	(0.26)	$	(0.24)	$	0.04